suppress
protect
immun
shown
patient
although
sever
hypothes
formul
mechan
denvinduc
immunosuppress
remain
unclear
previous
found
crossreact
antibodi
tumor
necrosi
factorrel
apoptosisinduc
ligand
trail
receptor
death
receptor
elicit
dhf
patient
autoantibodi
fraction
elicit
nonstructur
protein
immun
experiment
mice
studi
found
antibodi
could
suppress
b
lymphocyt
function
vitro
vivo
treatment
immunoglobulin
ig
induc
caspasedepend
cell
death
immort
b
lymphocyt
raji
cell
vitro
ig
elicit
immun
markedli
suppress
mous
spleen
transit
b
igm
igd
bone
marrow
preprob
preb
matur
b
cell
igd
subset
mice
furthermor
function
analysi
reveal
preelicit
ig
titer
suppress
subsequ
neutral
antibodi
product
immun
denv
envelop
protein
data
suggest
elicit
titer
denv
immun
play
suppress
role
humor
immun
mice
dengu
viru
denv
mosquitoborn
singl
positivestrand
rna
viru
belong
flavivirida
famili
genu
flaviviru
major
serotyp
denv
caus
selflimit
dengu
fever
df
lifethreaten
dengu
hemorrhag
fever
dhf
estim
million
case
denv
infect
occur
approxim
patient
hospit
dhf
mainli
tropic
subtrop
region
evid
suggest
geograph
extens
denv
infect
increas
number
denv
case
diseas
sever
df
dhf
becom
major
public
health
problem
onethird
global
popul
resid
hightransmissionrisk
area
dhf
complex
diseas
mechan
remain
elus
current
specif
treatment
effect
vaccin
avail
dhf
prior
denv
infect
risk
factor
develop
dhf
secondari
infect
abnorm
immun
respons
consid
vital
compon
dhf
pathophysiolog
variou
studi
report
immunosuppress
patient
sever
denv
infect
littl
known
immun
system
disrupt
sever
hypothes
formul
explain
phenomenon
exampl
accord
wide
accept
hypothesi
antibodydepend
enhanc
ade
initi
first
step
instead
provid
protect
immun
preexist
nonneutr
antidenv
antibodi
form
immun
complex
denv
substanti
increas
infect
denv
target
fc
receptorexpress
leukocyt
suggest
denv
antibodycomplex
boost
viru
product
per
infect
cell
suppress
intracellular
antivir
respons
accordingli
ade
denv
secondarili
lead
increas
overal
viru
replic
leukocyt
suppress
leukocytemedi
immun
follow
second
later
step
nonneutr
antidenv
antibodi
elicit
ade
addit
explan
regard
denv
infect
lead
immunosuppress
first
step
prior
ade
requir
one
hypothesi
origin
antigen
sin
suggest
initi
immunosuppress
occur
ade
howev
detail
mechan
lead
product
nonneutr
antibodi
particularli
relev
b
cell
respons
remain
elus
clinic
cellular
anim
studi
found
denv
infect
denv
nonstructur
protein
immun
elicit
autoantibodi
plasma
platelet
endotheli
antigen
among
autoantigen
previou
report
suggest
endotheli
tnfrelat
apoptosisinduc
ligand
trail
receptor
death
receptor
also
known
could
potenti
autoantibodi
target
lead
plasma
leakag
sever
denv
infect
previou
studi
member
tnf
receptor
tnfr
famili
show
certain
structur
similar
tnfr
famili
member
taci
bcma
baffr
denv
also
elicit
crossreact
autoantibodi
target
taci
bcma
baffr
lymphocyt
regul
particularli
b
cell
function
may
therefor
impair
howev
possibl
yet
verifi
result
studi
hypothes
denv
infect
autoantibodi
may
gener
receptor
bcell
activ
factor
baff
also
known
bli
includ
bcell
matur
antigen
bcma
also
known
transmembran
activ
caml
interactor
taci
also
known
baff
receptor
baffr
also
known
baff
cytokin
belong
tumor
necrosi
factor
tnf
ligand
famili
mainli
express
b
lymphocyt
baff
express
vari
depend
b
cell
matur
baff
receptor
taci
bcma
baffr
express
b
cell
taci
found
subset
cell
bcma
found
plasma
cell
receptor
play
critic
role
regul
b
lymphocyt
prolifer
differenti
matur
activ
collect
involv
taci
bcma
baffr
autoantibodi
mediat
pathogenesi
dengu
may
worth
investig
therefor
extend
previou
experi
studi
investig
whether
serum
sampl
dhf
patient
denv
rabbit
contain
immunoglobulin
ig
fraction
taci
bcma
baffr
moreov
analyz
associ
induct
antideath
receptor
autoantibodi
fraction
lymphocyt
popul
neutral
antibodi
product
use
mous
model
discuss
potenti
immunosuppress
mechan
scientif
report
http
doiimmun
cycl
wk
interv
bone
marrow
spleen
lymphocyt
analyz
later
use
aforement
b
cell
marker
analyz
potenti
suppress
effect
prior
immun
later
induct
neutral
antibodi
mice
first
immun
rgst
rtaci
immun
cycl
immunogenmouseimmun
cycl
immun
addit
immun
cycl
denv
reiii
wk
interv
antieiii
titer
denvneutr
properti
polyclon
antibodi
fraction
analyz
statist
analys
mean
standard
deviat
statist
quantifi
data
calcul
use
microsoft
offic
excel
sigmaplot
spss
signific
data
examin
anova
follow
posthoc
bonferronicorrect
test
probabl
type
error
recogn
threshold
statist
signific
antitaci
antibodi
detect
dhf
patient
denv
rabbit
previou
studi
found
antitrail
receptor
antibodi
titer
serum
sampl
dhf
patient
denv
rabbit
death
receptor
famili
share
structur
similar
among
member
studi
investig
whether
antibodi
fraction
taci
bcma
baffr
present
serum
sampl
dhf
patient
denv
rabbit
analyz
antitaci
antibcma
antibaffr
ig
level
patient
infect
denv
use
enzymelink
immunosorb
assay
elisa
result
reveal
patient
dhf
tend
exhibit
higher
igg
titer
taci
compar
normal
donor
patient
df
fig
rabbit
ig
use
investig
whether
denv
immun
elicit
antitaci
titer
consist
previou
studi
elisa
data
show
titer
elicit
follow
immun
recombin
fig
notabl
ig
affinityenrich
fraction
ig
ig
could
still
recogn
taci
substrat
fig
taci
group
examin
vitro
determin
whether
surviv
b
cell
cell
influenc
antitaci
ig
analyt
data
show
treatment
rabbit
antitaci
ig
induc
consider
cell
death
immort
b
raji
jurkat
cell
line
fig
b
treatment
rabbit
antitaci
ig
also
increas
popul
suppl
fig
activ
fig
although
use
equal
dose
antitaci
ig
ig
treatment
induc
signific
cell
death
raji
jurkat
cell
igtreat
group
still
tend
exhibit
high
cell
death
activ
level
fig
suppl
fig
examin
whether
antideath
receptor
ig
fraction
fig
polyclon
ig
induc
cell
death
lymphoid
cell
line
use
affinityenrich
fraction
ig
ig
ig
plu
addit
protein
eg
recombin
glutathion
stransferas
rgst
neg
control
protein
recombin
recombin
taci
rtaci
recombin
perform
neutral
experi
data
indic
ig
treatment
induc
cell
death
raji
jurkat
cell
dose
depend
manner
suppl
fig
treatment
rgst
neutral
celldeath
induc
properti
ig
suppl
fig
b
addit
ig
fraction
prepar
anim
immun
singl
serotyp
alon
heterolog
serotyp
exhibit
similar
level
celldeath
induct
properti
suppl
fig
suggest
experiment
system
feasibl
autoantibodi
product
immun
anim
influenc
immun
singl
heterolog
serotyp
found
treatment
rtaci
consider
reduc
iginduc
cell
death
raji
jurkat
cell
fig
f
rtaci
ig
group
suggest
antitaci
subfract
ig
still
abl
induc
lymphocyt
cell
death
titer
high
enough
analyz
whether
antitaci
antibodi
fraction
caus
abnorm
lymphocyt
respons
vivo
first
analyz
cell
b
cell
popul
mice
immun
rgst
rtaci
immun
cycl
dhf
consid
associ
secondari
denv
infect
immun
cycl
protein
particularli
perform
found
antigst
antitaci
ig
titer
markedli
elicit
experiment
mice
immun
cycl
suppl
fig
follow
previous
describ
method
found
splenic
cell
popul
affect
immun
cycl
rgst
rtaci
suppl
fig
analyz
b
cell
marker
igm
igd
detect
matur
igd
igm
transit
igd
igm
igd
igm
b
cell
marker
identifi
follicular
int
margin
zone
b
cell
hi
also
analyz
splenic
b
cell
accord
previou
report
method
similar
result
cell
analysi
consider
chang
observ
splenic
b
cell
popul
includ
follicular
fo
int
margin
zone
mz
hi
b
cell
suppl
fig
mice
immun
recombin
protein
howev
earlier
development
stage
suppl
fig
consider
chang
observ
transit
igd
igm
igd
igm
b
cell
immun
fig
gst
vs
group
although
obviou
taci
group
tend
exhibit
similar
chang
fig
popul
increas
popul
suppress
fig
group
accord
b
cell
differenti
process
suppl
fig
antibodi
may
block
transit
cell
explan
consist
find
previou
studi
indic
primari
b
cell
express
trail
receptor
transit
b
cell
express
taci
investig
whether
immun
recombin
protein
influenc
differ
stage
b
cell
develop
analyz
bone
marrow
b
cell
use
b
cell
marker
igm
igd
detect
matur
igd
igm
igd
igm
immatur
igd
igm
b
cell
marker
identifi
preprob
preb
prob
cell
notabl
found
matur
igd
igm
igd
igm
immatur
igd
igm
b
cell
mous
bone
marrow
consider
decreas
immun
cycl
rgst
rtaci
fig
p
vs
respect
gst
group
consist
analys
fluoresc
label
b
cell
marker
reveal
preprob
preb
popul
upper
gate
area
cell
also
markedli
decreas
immun
fig
p
vs
respect
gst
group
moreov
immun
preexist
antibodi
reduc
product
neutral
antibodi
mice
elicit
ig
titer
associ
develop
abnorm
b
cell
subset
mous
spleen
bone
marrow
fig
although
total
circul
igm
igg
level
chang
suppl
fig
whether
b
cell
abnorm
suffici
result
suppress
humor
immun
remain
unclear
thu
perform
function
analysi
investig
whether
b
cell
abnorm
lead
immunosuppress
denv
envelop
protein
domain
iii
eiii
contain
glycosaminoglycan
properti
denv
util
eiii
bind
cell
surfac
receptor
enter
target
cell
thu
antidenv
eiii
neutral
antibodi
protect
effect
denv
infect
follow
experiment
method
previou
section
first
immun
mice
recombin
protein
rgst
rtaci
immun
cycl
immun
group
mice
recombin
eiii
reiii
addit
cycl
fig
experiment
outlin
hypothes
iginduc
b
lymphocyt
defect
suffici
result
wwwnaturecomscientificreport
wwwnaturecomscientificreport
suppress
humor
immun
would
observ
lower
antieiii
antibodi
titer
consist
hypothesi
rel
lower
antieiii
ig
titer
elicit
mice
preimmun
fig
p
vs
adjuv
gst
group
analyz
whether
antieiii
ig
also
display
differ
protect
properti
denv
infect
use
antieiii
ig
differ
mous
group
protect
cell
denv
infect
vitro
notabl
antieiii
sera
adjuv
rgst
rtacipreimmun
mice
display
consider
protect
effect
denv
infect
compar
untreat
control
group
fig
adjuv
gst
taci
group
p
howev
antieiii
sera
mice
display
signific
protect
effect
fig
group
coeffici
determin
rsquar
r
analysi
reveal
antieiii
igg
level
inde
posit
correl
protect
cell
viabil
denvinfect
cell
suppl
fig
result
collect
suggest
elicit
crossreact
ig
caus
abnorm
develop
bone
marrow
b
cell
result
suppress
humor
immun
mice
bone
marrow
igm
b
cell
precursor
suppress
immun
flow
cytometri
analysi
bone
marrow
b
cell
subset
use
igd
igm
marker
perform
mice
immun
gst
b
taci
c
recombin
protein
quantif
analys
reveal
matur
b
cell
popul
igd
igm
igd
igm
gate
immatur
b
cell
igd
igm
bone
marrow
significantli
suppress
immun
gst
taci
immun
e
p
compar
respect
gst
group
n
independ
experi
replic
http
wwwnaturecomscientificreport
wwwnaturecomscientificreport
preexist
nonneutr
enhanc
antibodi
crucial
induc
ade
phenomenon
denv
infect
unclear
nonneutr
ig
elicit
ade
phenomenon
recent
find
suggest
even
neutral
ig
dose
neutral
concentr
exhibit
enhanc
properti
antidenv
eiii
monoclon
antibodi
mab
deriv
immort
memori
b
cell
patient
primari
secondari
infect
either
serotyp
specif
crossreact
potent
neutral
denv
infect
howev
notabl
find
mab
enhanc
infect
subneutr
concentr
evid
suggest
even
ig
concentr
suffici
high
neutral
antibodi
produc
b
cell
may
still
induc
pathogen
ade
effect
studi
found
preexist
ig
could
suppress
neutral
antibodi
titer
mice
subsequ
immun
denv
eiii
fig
find
provid
possibl
explan
product
nonneutr
subneutr
antibodi
ade
anoth
puzzl
aspect
humor
immun
suppress
denv
infect
delay
induct
antidenv
ig
secondari
denv
infect
one
valuabl
observ
denvendem
region
figur
bone
marrow
preprob
cell
suppress
immun
flow
cytometri
analysi
bone
marrow
b
cell
precursor
use
marker
perform
mice
immun
gst
b
taci
c
recombin
protein
quantif
analys
reveal
preprob
preb
cell
popul
bone
marrow
significantli
suppress
immun
gst
taci
immun
e
p
compar
respect
gst
group
n
independ
experi
replic
wwwnaturecomscientificreport
wwwnaturecomscientificreport
preval
antidenv
antibodi
gener
popul
reach
observ
suggest
major
popul
endem
region
alreadi
infect
denv
least
case
infect
ordinari
pathogen
rapid
anamnest
antibodi
respons
occur
within
day
antigen
reencount
howev
antidenv
ig
display
late
induct
peak
day
fever
onset
secondari
infect
dhf
patient
relev
mechan
unclear
accord
origin
antigen
sin
hypothesi
weak
immun
respons
occur
secondari
denv
infect
howev
mechan
elicit
insuffici
humor
immun
dengu
remain
elus
studi
found
preexist
antibodi
fraction
could
suppress
b
cell
develop
fig
subsequ
elicit
neutral
antibodi
denv
fig
addit
result
reveal
ig
affect
immatur
b
cell
precursor
fig
suppress
newli
produc
b
cell
secondari
denvinfect
host
may
result
prefer
antibodi
product
matur
b
cell
clone
develop
primari
infect
thu
compar
origin
antigen
sin
hypothesi
suppress
effect
denvelicit
antideath
receptor
ig
antibodi
product
b
cell
altern
explan
phenotyp
bias
suppress
humor
immun
well
delay
weak
induct
antidenv
antibodi
secondari
infect
suppl
fig
studi
demonstr
denv
elicit
antideath
receptor
ig
fraction
also
demonstr
elicit
fraction
associ
abnorm
popul
bone
marrow
splenic
b
cell
precursor
suppress
humor
immun
data
reveal
although
elicit
antitaci
ig
statist
signific
compar
elicit
ig
fraction
antitaci
ig
still
tend
exert
suppress
effect
certain
condit
eg
fig
interact
taci
bcma
baffr
b
cell
baff
enhanc
b
cell
differenti
activ
baff
overexpress
associ
autoantibodi
product
autoimmun
diseas
baff
promot
autoantibodi
product
tacidepend
activ
transit
b
cell
taci
play
critic
role
regul
b
cell
differenti
activ
taci
mice
exhibit
accumul
activ
b
cell
taci
defici
lead
autoimmunepron
phenotyp
contrast
tacifc
lead
decreas
b
cell
number
potent
block
humor
immun
respons
furthermor
induct
taci
express
level
enhanc
b
cell
apoptosi
vivo
similar
taci
defici
defici
trail
receptor
lead
inflammationpron
phenotyp
trail
mice
suscept
arthriti
diabet
moreov
recombin
trail
demonstr
inhibit
autoimmun
diseas
numer
anim
model
rheumatoid
arthriti
autoimmun
encephalomyel
autoimmun
thyroid
trail
sensit
b
cell
apoptosi
induc
b
cell
apoptosi
crosslink
cell
surfac
receptor
ig
induc
similar
signal
nativ
ligand
trail
find
collect
suggest
wwwnaturecomscientificreport
wwwnaturecomscientificreport
taci
pathway
play
neg
role
regul
immun
homeostasi
may
explain
elicit
ig
suppress
humer
immun
vivo
immun
elicit
antitaci
ig
fraction
studi
fig
synergi
antibodi
fraction
may
theoret
possibl
worth
investig
denvelicit
preexist
antibodi
hypothes
affect
secondari
denv
infect
mani
way
exampl
antibodi
depend
enhanc
ade
viral
uptak
fcrbear
cell
product
infect
antiplatelet
antiendotheli
cell
autoantibodi
associ
thrombocytopenia
vascular
leakag
summar
integr
result
describ
report
previou
find
postul
hypothet
model
follow
time
line
dhf
pathogenesi
suppl
fig
base
model
level
antiplatelet
antiendotheli
cell
autoantibodi
fraction
secondhit
suffici
elicit
hemorrhag
pathogenesi
denvinduc
defect
firsthit
cooccur
accordingli
elev
level
autoantibodi
suppress
b
cell
develop
could
therebi
reduc
antidenvneutr
ig
product
lead
stronger
denv
first
hit
induc
damag
thu
result
increas
risk
develop
dhf
suppl
fig
antidenv
ig
crossreact
virusig
complex
subsequ
induc
antibodi
depend
enhanc
ade
relat
pathogenesi
exacerb
diseas
suppl
fig
summari
report
elicit
antideath
receptor
antibodi
fraction
immun
suppress
b
cell
develop
fig
denvneutr
antibodi
product
find
may
explain
induct
suppress
humer
immun
denv
infect
addit
concept
may
use
develop
effect
safe
denv
vaccin
human
mous
behav
differ
respons
denv
infect
clinic
studi
need
clarifi
exact
respons
regul
patient
sever
dengu
denv
recombin
protein
antibodi
strain
solubl
recombin
protein
denv
obtain
purifi
use
previous
describ
method
recombin
human
tnf
receptorectodomainigg
fc
fusion
protein
igg
fc
igg
fc
igg
fc
igg
fc
bcmaigg
fc
rbcmafc
baffrigg
fc
rbaffrfc
purchas
r
system
minneapoli
mn
recombin
denv
envelop
protein
domain
iii
eiii
purchas
prospec
east
brunswick
nj
recombin
taci
ectodomain
rtaci
express
escherichia
coli
preimmun
ig
ig
new
zealand
white
rabbit
oryctolagu
cuniculu
obtain
immun
recombin
protein
ig
prepar
recombin
rabbit
describ
antitaci
ig
prepar
rtaciimmun
rabbit
serum
sampl
protein
immun
rabbit
collect
day
th
immun
cycl
aforement
recombin
protein
enhanc
immun
effici
rabbit
mous
experi
recombin
protein
emulsifi
complet
freund
adjuv
sigmaaldrich
st
loui
mo
first
immun
later
boost
cycl
incomplet
freund
adjuv
sigmaaldrich
use
vv
mix
recombin
protein
wwwnaturecomscientificreport
wwwnaturecomscientificreport
describ
induct
igg
titer
specif
antigen
confirm
use
enzymelink
immunosorb
assay
elisa
batch
rabbit
immun
antisera
rabbit
rel
higher
antitaci
igg
titer
use
igg
fraction
obtain
purifi
rabbit
serum
sampl
use
proteina
column
connect
peristalt
pump
ge
healthcar
life
scienc
littl
chalfont
uk
oper
flow
rate
ml
min
describ
ig
prepar
protein
afract
ig
affin
purif
use
rtaciconjug
bead
respect
use
sdspage
nihimag
j
softwar
version
purifi
ig
estim
approxim
pure
experiment
mice
rabbit
maintain
specif
pathogen
free
condit
consist
temperatur
humid
control
h
lightdark
cycl
protocol
use
rabbit
mous
experi
carri
accord
guidelin
approv
institut
anim
care
use
committe
tzuchi
univers
approv
id
patient
sampl
use
guidelin
report
dengu
case
df
dhf
classifi
serum
sampl
collect
describ
df
case
classifi
manifest
fever
accompani
least
follow
symptom
sever
headach
retroorbit
pain
myalgia
arthralgia
rash
dhf
case
also
defin
accord
clinic
manifest
well
addit
hemorrhag
manifest
includ
posit
tourniquet
test
result
hemoconcentr
addit
sign
plasma
leakag
follow
previous
describ
method
serum
sampl
collect
patient
test
use
least
follow
method
viru
infect
isol
mosquito
cell
serotypespecif
rtpcr
denvspecif
igm
igg
measur
hemagglutin
inhibit
test
serum
sampl
collect
onset
fever
denvspecif
igm
igg
antibodi
analyz
use
antidengu
igm
igg
captur
elisa
kit
panbio
brisban
australia
accord
manufactur
instruct
person
inform
patient
donor
deidentifi
sampl
aggreg
data
use
data
analysi
protocol
studi
concern
human
subject
conduct
accord
guidelin
approv
institut
review
board
approv
id
inform
consent
obtain
particip
andor
legal
guardian
standard
elisa
protocol
use
determin
antibodi
titer
patient
rabbit
rgst
rtaci
recombin
fusion
protein
includ
bcmafc
tacifc
per
well
coat
microtit
plate
bind
substrat
incub
patient
sera
dilut
purifi
rabbit
ig
level
substratebound
ig
probe
use
specif
horseradish
peroxidaseconjug
antibodi
measur
describ
previous
cell
line
cell
viabil
caspas
activ
analys
jurkat
atcc
immort
line
human
lymphocyt
raji
atcc
immort
line
human
b
lymphocyt
maintain
rpmi
cell
cultur
medium
supplement
fetal
bovin
serum
fb
mm
glutamin
unitsml
penicillin
streptomycin
base
standard
cell
cultur
protocol
cell
viabil
cell
line
analyz
use
kit
roch
life
scienc
penzberg
germani
tetrazolium
salt
cleav
solubl
formazan
succinatetetrazolium
reductas
system
activ
metabol
intact
cell
formazan
measur
nm
use
elisa
reader
molecular
devic
sunnyval
ca
surviv
jurkat
raji
cell
measur
treatment
vari
antibodi
h
h
group
ig
treat
cell
also
appli
analysi
conduct
use
caspaseact
assay
kit
purchas
r
system
minneapoli
mn
usa
babi
hamster
kidney
cell
atcc
maintain
dmem
fb
gl
glucos
mm
glutamin
cell
cultur
medium
use
analysi
antienvelop
eiii
protein
neutral
antibodi
serum
sampl
mice
immun
cycl
recombin
gst
taci
addit
cycl
recombin
denv
eiii
collect
place
water
bath
inactiv
complement
cell
cultur
well
dish
serum
free
medium
aforement
antisera
supplement
microtit
plate
cell
surviv
analyz
challeng
without
denv
moi
h
use
kit
roch
mosquito
aed
albopictu
cell
line
atcc
maintain
use
emem
ebss
fb
mm
glutamin
use
identif
denv
patient
serum
sampl
mous
b
cell
analys
wild
type
mice
age
week
purchas
nation
laboratori
anim
center
taipei
taiwan
anim
hous
tzuchi
univers
anim
center
specificpathogenfre
temperatur
light
control
environ
free
access
filter
water
food
experiment
procedur
approv
anim
care
use
committe
tzuchi
univers
approv
id
fluorescencelabel
antiigm
antiigd
ig
use
flow
cytometri
b
lymphocyt
analys
purchas
ebiosci
san
diego
ca
bd
bioscienc
franklin
lake
nj
antiigm
antiigd
use
identifi
subset
describ
ig
use
identifi
spleen
b
cell
subset
follow
previous
describ
method
follow
previous
describ
method
analyz
spleen
transit
follicular
margin
zone
matur
b
cell
bone
marrow
matur
igd
igm
igd
igm
immatur
igd
igm
b
cell
preprob
preb
prob
cell
flow
cytomet
facscalibur
bd
bioscienc
san
jose
ca
usa
use
studi
describ
mice
immun
rgst
rtaci
immun
cycl
immunogenmous
